SCHEMBL22296709

SCHEMBL22296709

CCC(=O)c1ccc(CCC(C)C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.47
MAPT P10636 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
DPP4 P27487 4/20 0.44
THRA P10827 3/20 0.44
THRB P10828 3/20 0.44
ABCB1 P08183 1/20 0.43
KMT2A Q03164 4/20 0.43
RAB9A P51151 3/20 0.43
MEN1 O00255 3/20 0.43
GRIN2D O15399 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
NPC1 O15118 1/20 0.43
HTT P42858 2/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20278348 0.84 MAPT (0.57) SMN1; SMN2MAPTL3MBTL1THRATHRB
SCHEMBL6140804 0.84 GSK3B (0.53) SMN1; SMN2L3MBTL1DPP4THRATHRB
SCHEMBL8834347 0.82 CES2 (0.52) SMN1; SMN2MAPTDPP4THRATHRB
SCHEMBL8834346 0.82 DPP4 (0.46) SMN1; SMN2MAPTL3MBTL1DPP4KMT2A
SCHEMBL104594 0.81 GRIN2D (0.57) SMN1; SMN2MAPTL3MBTL1THRBKMT2A
SCHEMBL12018041 0.81 KMT2A (0.57) SMN1; SMN2MAPTL3MBTL1KMT2ARAB9A
SCHEMBL2140146 0.81 PTGS1 (0.52) SMN1; SMN2MAPTL3MBTL1KMT2AMEN1
SCHEMBL28049827 0.81 PLK1 (0.45) SMN1; SMN2MAPTL3MBTL1DPP4THRA
SCHEMBL11576141 0.80 KMT2A (0.50) SMN1; SMN2MAPTL3MBTL1DPP4KMT2A
SCHEMBL10021819 0.80 L3MBTL1 (0.67) SMN1; SMN2MAPTL3MBTL1THRATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-25 US disclosed
EP-3510022-B1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2020-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF HDAC6, PSMG3, PSMB2 SMN1; SMN2 991/4885MAPT 533/4885L3MBTL1 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.